HCA
MYGN icon

Harbor Capital Advisors’s Myriad Genetics MYGN Stock Holding History

Harbor Capital Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$556K Buy
97,375
+9,689
+11% +$44K 0.04% 506
2026
Q1 		$395K Buy
+87,686
New +$457K 0.03% 522

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Harbor Capital Advisors's MYGN Position: Q2 2026 in Review

Harbor Capital Advisors increased its Myriad Genetics (MYGN) stake by 11% in Q2 2026, buying an estimated $44K and bringing the position to 97,375 shares worth $556K. The position accounts for 0.04% of the portfolio, ranked #506.

Harbor Capital Advisors first reported a position in MYGN in Q1 2026 and has held it in 2 quarters since. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Harbor Capital Advisors held 97,375 shares of Myriad Genetics worth $556K as of Q2 2026.
  • Harbor Capital Advisors bought 9,689 Myriad Genetics shares in Q2 2026, an estimated $44K.
  • Myriad Genetics made up 0.04% of Harbor Capital Advisors's portfolio in Q2 2026, its #506 holding.
  • Harbor Capital Advisors first reported a position in Myriad Genetics in Q1 2026 and has held it in 2 quarters since.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Harbor Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.